JP2009517343A5 - - Google Patents

Download PDF

Info

Publication number
JP2009517343A5
JP2009517343A5 JP2008540240A JP2008540240A JP2009517343A5 JP 2009517343 A5 JP2009517343 A5 JP 2009517343A5 JP 2008540240 A JP2008540240 A JP 2008540240A JP 2008540240 A JP2008540240 A JP 2008540240A JP 2009517343 A5 JP2009517343 A5 JP 2009517343A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
scf
vector
delivered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008540240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517343A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/043937 external-priority patent/WO2007059010A2/en
Publication of JP2009517343A publication Critical patent/JP2009517343A/ja
Publication of JP2009517343A5 publication Critical patent/JP2009517343A5/ja
Pending legal-status Critical Current

Links

JP2008540240A 2005-11-14 2006-11-13 組織損傷のための幹細胞因子療法 Pending JP2009517343A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73705805P 2005-11-14 2005-11-14
PCT/US2006/043937 WO2007059010A2 (en) 2005-11-14 2006-11-13 Stem cell factor therapy for tissue injury

Publications (2)

Publication Number Publication Date
JP2009517343A JP2009517343A (ja) 2009-04-30
JP2009517343A5 true JP2009517343A5 (cg-RX-API-DMAC7.html) 2010-01-07

Family

ID=38049189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008540240A Pending JP2009517343A (ja) 2005-11-14 2006-11-13 組織損傷のための幹細胞因子療法

Country Status (7)

Country Link
US (1) US8404653B2 (cg-RX-API-DMAC7.html)
EP (1) EP1948246B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009517343A (cg-RX-API-DMAC7.html)
CN (1) CN101563097A (cg-RX-API-DMAC7.html)
AU (1) AU2006315601A1 (cg-RX-API-DMAC7.html)
CA (1) CA2629775A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007059010A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440617B2 (en) * 2007-03-22 2013-05-14 The Trustees Of The University Of Pennsylvania Hyperbaric treatment in wound healing
JP5467742B2 (ja) * 2007-08-24 2014-04-09 国立大学法人 岡山大学 Ecpを有効成分とする左室リモデリングの予防及び治療剤。
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
WO2013152230A1 (en) 2012-04-04 2013-10-10 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
GB201400562D0 (en) 2014-01-14 2014-03-05 Orla Protein Technologies Ltd Protein coated polymeric substrate
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
US12246057B2 (en) 2018-04-13 2025-03-11 Board Of Regents, The University Of Texas System Transmembrane stem cell factor (tm-SCF) lipid nanocarriers and methods of use thereof
CA3136626A1 (en) * 2019-04-12 2020-10-15 Emory University Compositions and methods for promoting hematopoietic cell cytotoxicity

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US4036228A (en) 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4016880A (en) 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4203442A (en) 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4210139A (en) 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5387419A (en) 1988-03-31 1995-02-07 The University Of Michigan System for controlled release of antiarrhythmic agents
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
EP0676470A1 (en) 1989-10-16 1995-10-11 Amgen Inc. Stem cell factor
US6759215B1 (en) 1989-10-16 2004-07-06 Amgen Inc. Method of preparing human stem cell factor polypeptide
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5681278A (en) 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5827216A (en) 1995-06-07 1998-10-27 Cormedics Corp. Method and apparatus for accessing the pericardial space
US5900433A (en) 1995-06-23 1999-05-04 Cormedics Corp. Vascular treatment method and apparatus
ES2240999T3 (es) * 1995-08-29 2005-10-16 Anges Mg, Inc. Medicamento que contiene un gen del hgf.
GB9519776D0 (en) 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
DE69720190T2 (de) 1996-02-02 2003-12-11 Alza Corp Implantierbares system mit verzögerter freisetzung von leuprolid
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
CA2213906A1 (en) * 1996-09-23 1998-03-23 Dusica Maysinger Pharmaceutical composition and method for neuron rescue in ischemic stroke
US6258119B1 (en) 1996-11-07 2001-07-10 Myocardial Stents, Inc. Implant device for trans myocardial revascularization
US5931810A (en) 1996-12-05 1999-08-03 Comedicus Incorporated Method for accessing the pericardial space
US6443949B2 (en) 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
CA2294944A1 (en) 1997-07-03 1999-01-14 Osiris Therapeutics, Inc. Human mesenchymal stem cells from peripheral blood
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US6251418B1 (en) 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US7078387B1 (en) * 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
WO2002030443A2 (en) 2000-10-11 2002-04-18 The Wistar Institute Regulation of human skin healing
WO2002076344A1 (en) 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US7605128B2 (en) * 2002-02-14 2009-10-20 Buck Institute For Age Research Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
EP1654365A1 (en) 2003-08-11 2006-05-10 University Of South Florida Vigilant cells
WO2005053729A1 (en) * 2003-11-26 2005-06-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stem cell factor for inducing neural stem cell migration to areas of neurological injury
CA2557480A1 (en) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolating cardiac circulation
AU2005306894B2 (en) * 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders

Similar Documents

Publication Publication Date Title
Rufaihah et al. Dual delivery of VEGF and ANG-1 in ischemic hearts using an injectable hydrogel
CN104884076B (zh) 利用了hmgb1片段的心肌梗塞的治疗方法
WO2006121532A3 (en) Treatment for heart disease
Favaloro et al. High‐dose plasmid‐mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis‐I). A phase I, open‐label, two‐year follow‐up trial
JP2009545310A5 (cg-RX-API-DMAC7.html)
US7125856B1 (en) Angiogenic growth factors for treatment of peripheral neuropathy
CN103800045A (zh) 一种医疗用心脏填塞物
CA2354029A1 (en) Gene therapy for cardiomyopathy
Alijani-Ghazyani et al. Transplantation of umbilical cord-derived mesenchymal stem cells overexpressing lipocalin 2 ameliorates ischemia-induced injury and reduces apoptotic death in a rat acute myocardial infarction model
JP2019521976A5 (cg-RX-API-DMAC7.html)
Garoushi et al. Fiber-reinforced onlay composite resin restoration: a case report
Kusumoto et al. Cyclophosphamide-induced cardiotoxicity with a prolonged clinical course diagnosed on an endomyocardial biopsy
AU782819B2 (en) Angiogenic growth factors for treatment of peripheral neuropathy
JP2009500045A5 (cg-RX-API-DMAC7.html)
Nie et al. Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model
ES2566344T3 (es) VEGF-A para inducir regeneración del tejido miocárdico
CN102056602A (zh) 决奈达隆用于预防心脏复律
JP2012524781A5 (cg-RX-API-DMAC7.html)
Stamm et al. Cardiac cell therapy: A realistic concept for elderly patients?
EP1948246A2 (en) Stem cell factor therapy for tissue injury
CN101422462B (zh) 磷酸川芎嗪作为制备治疗扩张型心肌病的药物中的应用
JP2010510218A5 (cg-RX-API-DMAC7.html)
Ruiz-Garcia et al. Cardiac shock-wave therapy in the treatment of refractive angina pectoris
JP2005508829A5 (cg-RX-API-DMAC7.html)
US20230364267A1 (en) Pre-clinical modified rna approaches used in large animals for muscle and vascular regeneration